Mohammad Mahdi Hayatbakhsh1, Arezoo Gowhari Shabgah2,3, Saeed Pishgouyi4, Jalil Tavakol Afshari2,3, Hadi Zeidabadi5, Mojgan Mohammadi2,6. 1. Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology sciences, Kerman University of Medical Sciences, Kerman, Iran. 2. Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. 5. Department of Gastroenterology, Afzalipour hospital, Kerman University of Medical Sciences, Kerman, Iran. 6. Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
BACKGROUND: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by altered bowel habits and abdominal pain in the absence of a recognizable structural anomaly. The pathogenesis of IBS has been associated with inflammation and the expression of pro-inflammatory chemokines, such as CCL2 and CCL16. Our study aimed to investigate the relationship between the serum levels of CCL2 and CCL16 and IBS. Additionally, we examined how serum levels of these chemokines relate to IBS subtypes. METHODS: Patients with IBS diagnosed according to the Rome III criteria participated in this study (n= 96). Healthy individuals with no history of allergic, autoimmune, chronic or active gastrointestinal infectious diseases were used as controls (n= 44). The serum levels of CCL2 and CCL16 was measured via enzyme-linked immunosorbent assay (ELISA). RESULTS: A significant decrease in the serum levels of CCL16 and CCL2 was observed in the patients with IBS. Additionally, the serum levels of CCL16 in IBS patients with diarrhea (D-IBS) was significantly higher than those with the mixed IBS (M-IBS) subtype. CONCLUSION: The significant increase in the serum levels of CCL-16 in patients with D-IBS compared to patients with M-IBS suggests that CCL-16 may be used as an immunological biomarker to differentiate between these two subtypes.
BACKGROUND: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by altered bowel habits and abdominal pain in the absence of a recognizable structural anomaly. The pathogenesis of IBS has been associated with inflammation and the expression of pro-inflammatory chemokines, such as CCL2 and CCL16. Our study aimed to investigate the relationship between the serum levels of CCL2 and CCL16 and IBS. Additionally, we examined how serum levels of these chemokines relate to IBS subtypes. METHODS: Patients with IBS diagnosed according to the Rome III criteria participated in this study (n= 96). Healthy individuals with no history of allergic, autoimmune, chronic or active gastrointestinal infectious diseases were used as controls (n= 44). The serum levels of CCL2 and CCL16 was measured via enzyme-linked immunosorbent assay (ELISA). RESULTS: A significant decrease in the serum levels of CCL16 and CCL2 was observed in the patients with IBS. Additionally, the serum levels of CCL16 in IBS patients with diarrhea (D-IBS) was significantly higher than those with the mixed IBS (M-IBS) subtype. CONCLUSION: The significant increase in the serum levels of CCL-16 in patients with D-IBS compared to patients with M-IBS suggests that CCL-16 may be used as an immunological biomarker to differentiate between these two subtypes.
Authors: A Y Del Valle-Pinero; A C Martino; T J Taylor; B L Majors; N S Patel; M M Heitkemper; W A Henderson Journal: Neurogastroenterol Motil Date: 2011-09-23 Impact factor: 3.598
Authors: H Nomiyama; K Hieshima; T Nakayama; T Sakaguchi; R Fujisawa; S Tanase; H Nishiura; K Matsuno; H Takamori; Y Tabira; T Yamamoto; R Miura; O Yoshie Journal: Int Immunol Date: 2001-08 Impact factor: 4.823
Authors: George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Isabella de Araújo Esteves Duarte; Dragan Milenkovic; Tatiana Karla Dos Santos Borges; Artur Jordão de Magalhães Rosa; Christine Morand; Livia de Lacerda de Oliveira; Ana Maria Costa Journal: Nutrients Date: 2020-04-16 Impact factor: 5.717